RA33 is a nuclear autoantigen with an apparent molecular mass of33 kD. Autoantibodies against RA33 are found in about 30% of sera from RA patients, but only occasionally in sera from patients with other connective tissue diseases. To characterize RA33, the antigen was purified from HeLa cell nuclear extracts to more than 90% homogeneity by affinity chromatography on heparin-Sepharose and by chromatofocusing. Sequence analysis of five tryptic peptides revealed that their sequences matched corresponding sequences of the A2 protein of the heterogeneous nuclear ribonucleoprotein (hnRNP) complex. Furthermore, RA33 was shown to be present in the 40S hnRNP complex and to behave indistinguishably from A2 in binding to single stranded DNA. In summary, these data strongly indicate that RA33 and A2 are the same protein, and thus identify on a molecular level a new autoantigen. (J. Clin.
Introduction
RA is the most common autoimmune disease and affects 1-2% of the population. Despite many years of intensive research, the etiology of the disease is still poorly understood, and no definite cure is known ( 1) . Sera from patients with RA are primarily characterized by the presence of rheumatoid factor, an autoantibody directed against the Fc portion of IgG (2) . In addition, autoantibodies against components of the cell nucleus (antinuclear antibodies) and against EBV-related structures are frequently observed (3) (4) (5) . However, neither rheumatoid factor nor any of the other autoantibodies have been found to be specific for RA. Recently, autoantibodies against a nuclear protein with an apparent molecular mass of 33 kD have been described (6) . These autoantibodies were detected in 35% of RA patients but apart from a few exceptions not in sera from patients suffering from other autoimmune or degenPortions of this paper have appeared in abstract form in FASEB (Fed.
Am. Soc. Exp. Biol.) J. 1990. 4:A3259; and Clin. Rheumatol. 1990. 9:576. erative rheumatic disorders. Therefore, the antigen was termed RA33; this was the first description of a nuclear antigen apparently specific for RA.
Disease specific immune responses to nuclear antigens have been found for various autoimmune diseases: anti-Sm and anti-dsDNA in systemic lupus erythematosus (SLE), antitopoisomerase (ScI70) in scleroderma, or anti-tRNA synthetase in dermato/polymyositis are just a few examples. Other autoantibodies, such as anti-U 1 small nuclear ribonucleoprotein (snRNP),' anti-Ro/SS-A, anti-La/SS-B, or antihistone, are less specific but nevertheless, they do form valuable tools for the diagnosis of connective tissue diseases (for a review, see 7) . In general, the target antigens are molecules conserved in evolution, many of which have the capacity to bind DNA or RNA, such as histones, topoisomerase, or snRNP particles involved in posttranscriptional processing of pre-mRNA (8) .
In contrast to snRNPs (9, 10), components ofthe heterogeneous nuclear ribonucleoprotein (hnRNP) complex have only rarely been described as target structures for human autoantibodies ( 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . So far, only the Al protein has been identified as autoantigen in a variety of autoimmune diseases (14, 15) . HnRNPs are large nuclear structures composed of heterogeneous nuclear RNA and 30 different proteins with molecular masses between 34 and 120 kD ( 16) . Six of these proteins (Al, A2, B 1, B2, C 1, C2) have been referred to as the hnRNP "core" proteins ( 17) , and the sequences of their cDNAs have been recently elucidated (18) (19) (20) (21) (22) . They belong to a group of nucleic acid binding proteins that contain an evolutionarily highly conserved RNA binding domain of -90 amino acids, the so-called consensus sequence-type RNA binding domain (CS-RBD [23] ). Little is known about the detailed structure and function of the hnRNP complex, but there is some evidence for a functional relationship to the snRNPs (24) .
In this report, we describe the purification and partial sequencing of RA33. Furthermore, it is demonstrated that RA33 is present in the 40S hnRNP complex, and that it is indistinguishable from the A2 protein in affinity chromatography on single stranded DNA (ssDNA). Taken together, the data strongly suggest that RA33 and A2 are identical.
Methods
Protein purification. HeLa S3 cells or nuclei were obtained frozen from the Computer Cell Culture Center, (University of Mons, Belgium).
Isolation of nuclei and preparation of nuclear extracts was performed as described (6) . Briefly, 10 g of nuclei were incubated for 30 min in 4 ml hypotonic buffer (10 mM Hepes-KOH, 2.5 mM MgCl2, 25% glycerol, pH 7.9) and subsequently extracted for 40 min by addition of an equal volume ofthe same buffer containing 0.88 M NH4C1. The slurry was centrifuged for 20 min at 20,000 g, and the NH4C1 concentration of the supernatant was adjusted to 0.3 M by diluting with 10 mM Hepes-KOH, pH 7.9. 40 ml nuclear extract ( -200 mg protein) was applied to a 2.5 x 20 cm heparin-Sepharose CL-6B column (Pharmacia, Uppsala, Sweden) equilibrated with buffer A (20 mM Hepes-NaOH, 0.3 M NaCl, pH 7.9). The column was washed with 3 vol of buffer A, and bound protein was eluted with 3 vol ofbuffer B (20 mM Hepes-NaOH, 1 M NaCl, pH 7.9) followed by 3 vol of buffer C (20 mM Hepes-NaOH, 1 M NaCl, 6 M urea, pH 7.9). Protein concentration of each fraction (10 ml) was measured in a microplate reader at 620 nm using the Coomassie Protein Assay Reagent from Pierce Chemical Co. (Rockford, IL). Protein-rich fractions were analyzed for the presence ofRA33 by immunoblotting, as described below. RA33 containing fractions were pooled ( 10 mgtotal protein), precipitated with 0.4 g/ml ammonium sulphate, and redissolved in chromatofocusing starting buffer (20 mM Tris-CH3COOH, 3 M urea, pH 8.7). After dialyzing against the same buffer, proteins were further separated by chromatofocusing on a 15 X 0.6 cm PBE 94 ion exchanger column (Pharmacia). A 1:8 diluted Polybuffer 96-acetic acid, pH 6, containing 3 M urea, was used as eluent (flow rate 8 ml/h, fraction size 2 ml). Aliquots were precipitated with 10% TCA, redissolved in Laemmli sample buffer and investigated by immunoblotting. Fractions containing RA33 were pooled, precipitated with ammonium sulphate, and redissolved in either 20 mM Tris-HCl, pH 7.5, containing 6 M urea, or trypsin sequencing buffer (see below).
Protein sequencing. 20 ,ug ofpurified RA33 were mixed with 0.1 ml of 125 mM ammonium bicarbonate, pH 7.5, containing 2 ug trypsin sequencing grade (Boehringer Mannheim GmbH, Mannheim, Germany) and incubated for 6 h at 37°C; an extra 2 ,ug of trypsin was added and incubation was continued for another 16 h. The resulting peptide fragments were separated by reversed phase HPLC on a 5 gm C18 column (Deltapak; Waters Associates, Millipore Corp., Milford, MA) using a linear 0-70% acetonitrile gradient in 0.1% trifluoroacetic acid. Five fractions corresponding to major peaks on the chromatogram were analyzed on a pulsed liquid phase sequenator (Type 477; Applied Biosystems, Inc., Foster City, CA).
ssDNA chromatography ofhnRNPparticles. HnRNP particles were extracted from intact nuclei as described by Beyer et al. ( 17) . Briefly, nuclei were resuspended in STM (saline-Tris-magnesium) buffer (10 mM Tris-HCl, 2.5 mM MgCl2, 0.1 M NaCl) at pH 7.0 and gently stirred for 30 min on ice. Nuclei were then pelleted at 700 g for 15 min, resuspended in STM, pH 8, and stirred on ice for another 30 min; this step was repeated twice. The pH 8 extracts were used for ssDNA chromatography ( 16): 4.5 ml of extract ( 10 mg protein) was loaded onto a 10 ml ssDNA agarose column (Bethesda Research Laboratories, Bethesda, MD) equilibrated with 50 mM phosphate buffer, pH 7.4, containing 0.1 M NaCl. After extensive washing of the column with the same buffer, bound protein was eluted stepwise with 0.2 M NaCl, 0.3 M NaCl, 0.5 M NaCl, and 2 M NaC1, all in 50 mM phosphate buffer, pH 7.4. Aliquots of protein containing fractions were precipitated with 10% TCA and analyzed by SDS-PAGE and immunoblotting.
Preparation of 40S hnRNP complexes. HeLa cells (Wisconsin) were grown in monolayers ( 175 cm2) in DME supplemented with 10% FCS and glutamine. Nucleoplasm was prepared from isolated nuclei by sonication in STM buffer, pH 7.4, essentially as described ( 16) , except that Triton X-100 was omitted during sonication and all subsequent steps. Volumes were adjusted so that six monolayers yielded 1 ml nucleoplasm. To prepare 40S hnRNP complexes, 0.5 ml of nucleoplasm were treated with 4 or 8 U/ml micrococcal nuclease (P-L Biochemicals, Inc., Milwaukee, WI) in the presence of 5 mM CaCl2 for 15 min at 30°C. The nuclease reaction was stopped by addition of EGTA to 20 mM. The nucleoplasm was then layered onto a 12-ml 10-30% sucrose gradient in RSB-100 and centrifuged at 40C for 14 h at 28,000 rpm in a rotor (SW40; Beckman Instruments, Fullerton, CA). For reference. dissociated 70S E. coli ribosomes were run in parallel. Gradients were fractionated from bottom to top into 0.7 ml fractions and their absorbence at 260 nm was determined. Protein was recovered from gradient fractions by TCA precipitation and was analyzed by immunoblotting with patient serum.
Gel electrophoresis and immunoblotting. Samples were usually analyzed on 12% SDS-polyacrylamide minigels ( (Fig. 1) ; as these fractions contained about 10 mg protein, RA33 was -20-fold enriched. In addition to RA33, two proteins with estimated molecular masses measuring 36 and 37 kD migrating slightly above RA33 were reactive with the serum used for immunodetection of RA33 ( Fig. 2 B , lane H-S). These proteins were not only reactive with the RA33 specific serum used in this experiment, but also with most anti-RA33 positive sera tested in addition (not shown) indicating an immunological relationship between these three antigens. The tained a > 90% pure preparation of RA33 as judged by Coomassie blue staining (Fig. 2 A, lane CHF) and immunoblotting ( Fig. 2 B, (21) . Fig. 3 shows the sequence of A2 and the positions of the sequenced peptides, labeled A-E. Thus, peptides A (AsnTyr-Tyr-Glu-Gln-Trp-Gly-Lys) and B (Gly-Phe-Gly-Phe-ValThr-Phe-Asp-Asp-His-Asp-Pro-Val-Asp-Lys) corresponded to amino acids 27-34 and 142-156 of A2, respectively. These residues are located in the evolutionarily conserved amino terminal parts ofthe molecule (CS-RBD I and II), with peptide B containing seven amino acids of the most highly conserved octapeptide region, the RNP consensus sequence (Fig. 3) . Peptides C, D and E (10, 15, and 20 amino acids, respectively) corresponded to A2 sequences situated outside the conserved region, and were therefore unique for this protein. In summary, the sequences of five peptides (68 amino acids corresponding to 20% of the A2 sequence) showed 100% identity with sequences of the A2/B1 protein of the hnRNP complex. Therefore, it was concluded that the protein sequenced was identical to A2 or B 1. RA33 binds to ssDNA agarose and is contained in the 40S hnRNP particle. On the basis of the sequencing data alone, it was not possible to distinguish between A2 and B 1. Moreover, the possibility could not be excluded that the RA33 preparation used for sequencing was a mixture ofRA33 and A2 /B 1. In other words, RA33 and A2/B1 could have been copurifying proteins migrating in SDS-PAGE as a single band. Therefore, it was necessary to demonstrate that RA33 was present in the hnRNP complex and exhibited the same properties as either A2 or Bl.
As most proteins of the hnRNP complex bind with intermediate or high affinity to RNA or ssDNA (16, 25) , binding of RA33 to ssDNA was investigated by fractionating a nuclear extract on ssDNA agarose as described in Methods. Bound proteins were eluted by gradually increasing the NaCl concentration from 0.1 to 2 M (Fig. 4 A) . With the exception ofthe C proteins, the hnRNP proteins are known to coelute from ssDNA agarose between 0.3 and 0.5 M NaCl (16) . Most of the proteins were collected in the flow-through of the column (0.1 M NaCl), and several weakly stained bands can be seen in the 0.2 and 0.3 M NaCl eluates. In the 0.5 M fraction, however, a dominant double band and a faint doublet slightly above are clearly visible in the 30-40 kD region: this pattern of doublet bands is similar to the characteristic pattern described for the A and B proteins which in oligomeric hnRNP complexes are present in the molar ratio 3A 1-3A2-I B I -1 B2 (17, 26) . The lower band ofthe dominant doublet was identified to be Al by the Al specific monoclonal antibody 4B 10 (16) (not shown) and an Al specific patient serum (Fig. 4 B, lanes B) . The upper band corresponding in size to A2 was immunostained by an RA33 specific serum (Fig. 4 B, lanes A) . This serum also stained the two minor bands above that most probably contained the B proteins. Interestingly, only trace amounts of other proteins were present in this fraction, whereas the 2 M eluate contained at least 20 different proteins.
In a second experiment, 40S hnRNP particles were isolated from a nuclear extract by sucrose gradient centrifugation. This procedure yielded a preparation of highly enriched hnRNP core proteins (17, 26) . Subsequently, the presence of RA33 was detected using the RA33 reference serum, which predominantly stained a band in the mol wt region of the A proteins ( Fig. 5) . The position ofthis band on the blot was indistinguishable from that of partially purified RA33, which was run in parallel on the same gel (Fig. 5 , lane H-S). The staining ofthis band was most pronounced in fractions sedimenting in the 30S-40S range (fractions 6-8), and could not be observed in fractions sedimenting below 30S (fractions 9-17). This band was not stained by the Al specific serum which reacted with a protein of slightly lower molecular mass (not shown). Thus, it was demonstrated by independent experimental approaches that RA33 was indistinguishable from the hnRNP core protein A2. The two immunoreactive proteins copurifying with RA33 in ssDNA chromatography could not be identified unambigously. However, their migration relative to Al and A2 on SDS gels appeared similar to that reported for the B 1 and B2 proteins of the hnRNP particle.
Frequency and diagnostic specificity of anti-RA33 (anti-A2). Purified RA33 was used as antigenic source on Western blots to show that the antigenic properties ofthe purified material were comparable to that contained in crude nuclear extracts. 15 RA33 positive sera were retested and found to be reactive also with highly purified RA33 (not shown). In addition, a total number of 120 sera from patients with RA, SLE, mixed connective tissue disease (MCTD), Sjogren's syndrome, polymyositis, scleroderma, reactive arthritis, osteoarthritis, and from healthy controls were investigated using a RA33 preparation partially purified by heparin-Sepharose chromatography (Table I) . Taken together, antibodies to semipuri- fied RA33 (i.e., A2 hnRNP) were detected in 10 of 30 RA patients, in 4 of 10 MCTD patients, in 2 of 10 SLE patients, and in none ofthe other patients suffering from various inflammatory and degenerative rheumatic diseases, and in none of the controls.
Discussion
The data presented here reveal that the previously described nuclear autoantigen RA33 is indistinguishable from the A2 hnRNP protein, one of the six core proteins of the hnRNP complex (17, 19, 21) . Evidence for this is based on the following observations: (a) the amino acid sequences of five tryptic peptides obtained from a highly purified RA33 preparation can be found in that of the A2 protein; (b) the chromatographic behavior of RA33 was indistinguishable from A2 in ssDNA affinity chromatography; (c) RA33 was contained in the 40S hnRNP particle isolated by sucrose gradient centrifugation; and (d) the molecular masses (estimated from SDS-PAGE) reported for RA33 and A2 are very similar, namely 33 kD for RA33 (6) and 32.5-36 kD for A2 (16, 17, 21, 27) . The sequencing data are also compatible with RA33 being the hnRNP core protein B1 which is identical to A2 except for a 12-amino acid insertion near the NH2 terminus (21) . How- (16, 17, 21, 27) . Next, the staining of the RA33 band and the 36-37 kD doublet (Fig. 2 , lane H-S) indicated that RA33 was present in severalfold excess over these two proteins. This is compatible with the assumed molar ratio of 3:1 for A2 to B I (and B2) in the hnRNP complex (26) . Finally, when the A/B core proteins were isolated by ssDNA chromatography (a method that can be used for partial purification of hnRNP proteins [16] ), the RA33 serum reacted with three antigens corresponding in size to A2, B 1 and B2. These antigens were apparently identical to the three antigens copurifying in heparin-Sepharose chromatography and (partially) in chromatofocusing. This interpretation is also compatible with the reported immuncrossreactivity of anti-A2 to Bl and B2: mouse antibodies affinity-purified from recombinant A2 bound not only to A2 but also to both B proteins (21) . Given the high degree of sequence homology between A2 and B 1, reactivity of both proteins with the same (auto) antibody would not be surprising. In fact, most RA33 positive sera have been found to be reactive also with the 36-and 37-kD antigens assumed to be B1 and B2 (28, 29, unpublished observation) .
In this context, it should also be mentioned that monoclonal antibodies raised against hnRNP proteins frequently recognize several different proteins (13, 30) . When the A / B proteins were isolated by ssDNA chromatography anti-RA33 antibodies clearly reacted with the A2 band (and also with both the B 1 and B2 band), but not with the Al band. This was important to demonstrate since (recombinant) A l has already been identified as an autoantigen in a variety of connective tissue diseases (14) . Even though A1 and A2 are related proteins sharing extensive sequence homologies in their NH2-terminal portions (21), anti-RA33 (A2) positive sera reacted only very infrequently with Al (unpublished observation). Since, however, their COOH-terminal parts are only distantly related one could speculate that the COOH-terminal part ofA2 contains the epitope(s) eliciting A2 specific immune responses.
So far, hnRNPs have been studied only occasionally as target structures for autoantibodies (11, 12) . In a study by Gelpi et al. (13) , antibodies against hnRNPs were detected with high frequency in anti-U 1 RNP positive sera. As these sera reacted with one or more ofthe hnRNP proteins no preferential targets for the reacting autoantibodies could be identified. More recently, antibodies to recombinant Al hnRNP were described in patients with various connective tissue diseases (14) . In contrast, a high disease specifity has been described for RA33 as antibodies against this protein were found almost exclusively in RA patients (6) . This high specificity was not fully maintained when purified RA33 (i.e., A2, was used as antigen in immunoblotting since anti-RA33 antibodies were also detected in 4 of 10 sera from patients with MCTD and in 2 of 10 SLE sera [ Table 1 ] ). Interestingly, these 6 sera contained antibodies to UlsnRNP in addition to anti-RA33; this could indicate the existence of crossreacting epitopes. The diagnostic value of anti-RA33 (anti-A2) is not severely impaired by this result since RA sera neither contain antibodies to UlsnRNP nor other specificities typically found in SLE sera (anti-DNA, antiSm, anti-Ro, anti-La). Nevertheless, the clinical significance of anti-RA33 in MCTD and SLE, as well as the possible crossreactivity of anti-RA33 and U1snRNP, remains to be determined and will be the subject of future studies. Most importantly, all sera from patients with reactive arthritis and osteoarthritis were found negative for anti-RA33. Thus, this autoantibody is extremely useful to serologically differentiate RA from other arthritic diseases, which is often difficult, especially in the early stages of these diseases.
Although the detailed function ofthe hnRNP core proteins is not fully understood, they are known to closely interact with heterogeneous nuclear RNA ( 17, 31, 32 ) . At least the C proteins ofthe hnRNP complex have been shown to be involved in processing ofpre-mRNA, thus demonstrating a functional and topographic link between hnRNPs and snRNPs (24, (33) (34) (35) (36) 
